Skip to main content

Technology Development for Single-Molecule Protein Sequencing


Receipt date: June 15, 2023

Expires on: June 16, 2023


The Funding Opportunity Announcement (FOA) PAR-21-247 solicits R43/R44 grant applications to accelerate innovation and early development in the emerging field of single-molecule protein sequencing (SMPS). This FOA is seeking novel technologies or significant improvements to existing technologies. Exploration of technologies other than those currently being commercialized is highly encouraged. The short-term goal of this initiative is technological improvements that lead to significant increases in one or more combinations of throughput, cost, accuracy, sensitivity, dynamic range, and scale. The long-term goal is to achieve technological advances that enable generation of protein sequencing data at sufficient scale, speed, cost and accuracy to use routinely in studies of genome biology and function, and in biomedical and clinical research in general.

This FOA seeks to fund technology development research efforts in instrumentation innovation and sample preparation/processing approaches for single-molecule protein sequencing. The technology development proposed should have the potential to significantly propel the field of SMPS forward in the next five years, and have the potential to have a large impact on future studies of genome biology or genome function in general, but particularly in the context of cancer, cancer therapy, infectious and immune-mediated diseases. The proposed research also must have the clear potential to scale proteome-wide. The technology proposed can innovate substantially novel approaches or significantly improve (i.e., no less than tenfold) existing methodologies for SMPS. The FOA deliberately does not specify cost, quality, scale, sensitivity, dynamic range, throughput, or other key metrics since achievable endpoints are likely to improve during the course of this initiative and can substantially differ from one technology to another. However, the applicant must propose quantitative metrics so progress can be evaluated, and have convincing rationale that the proposed technology has the potential to scale long-term and to achieve a throughput compatible with widespread adoption by the proteogenomics, biomedical and clinical research community.

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Technology Development for Single-Molecule Protein Sequencing was originally published by the National Cancer Institute.”